Agilent Technologies sells laboratory analytical instruments used across life-science research, quality control and contract development/manufacturing services, operating as a visible leader in the Laboratory Analytical Instruments industry with a market capitalization near $41.4 billion and listing on the NYSE.
The company’s revenue trend moved from modest year-over-year declines in 2023–early 2024 to consistent positive growth beginning in CY2024Q4; revenue has risen to $1.88 billion in CY2026Q2, up about 8.1% year-over-year, and the two most recent quarters show stronger sequential top-line momentum. GAAP diluted EPS has been more variable but improved in the latest quarters, with GAAP diluted EPS of $1.20 in CY2026Q1 (a 60% year-over-year increase) and $1.28 in CY2026Q2 (about +8.5% year-over-year). Revenue and earnings are growing, though reported metrics do not show acceleration flags in the growth-acceleration scoring.
Institutional participation is a material support: 95.47% of shares are held by institutions across 1,605 reporting holders, and top-holder activity is net positive on average, which aligns with recent outperformance versus the S&P 500 (about +9.8% excess return over three months). The company sits squarely in the Life Science Tools & CDMO theme and carries the traits of a market leader, but technicals flag a topping pattern and no fresh breakout setup is present, making timing relevant for prospective entries.
Why now
Revenue turned persistently positive year-over-year after earlier declines and the last two quarters show solid growth and GAAP EPS recovery, while institutional ownership is very high and relative strength has outperformed the S&P 500 over three months.
The setup
Technically the trend is constructive but not buy-ready: last close was $146.93 on 2026-09-11, above the 50-day average ($143.26) and 200-day average ($131.58) but slightly below the short EMAs (9-day EMA $148.09, 21-day EMA $148.73). Six of seven trend checks passed, with the single failed check around the 150-day vs 200-day moving average; the Weinstein stage is Stage 3 (topping) and the platform is labeled 'watch' because there is no verified fresh breakout or 9/21-day EMA add setup. Momentum is neutral (RSI 48.1) and the stock sits about 7.6% below its 52-week high.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (21 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $6.20 (+11%) · FY'27E $6.76 (+9%) — 21 analysts
Risks
1) Cyclical and budget-sensitive end markets: capital spending for lab instruments can ebb with pharma/biotech budgets, which would pressure revenue and reported GAAP EPS. 2) Mixed earnings trajectory: GAAP diluted EPS has been volatile quarter-to-quarter, and growth-acceleration scores do not indicate a clear earnings inflection. 3) Technical distribution risk: the Weinstein Stage 3 topping signal and absence of a confirmed breakout raise the risk of a pullback before any durable uptrend resumes, which could be amplified if institutional holders reduce positions.
Framework fit
CANSLIM
5/7- CCurrent quarterly GAAP EPS growth ≥ 25%+8%✕
- AAnnual GAAP EPS growth ≥ 25%+3%✕
- NNew highs — within 15% of 52-week high-7.59%✓
- SSupply/demand — up-day volume leads1.05x✓
- LLeader — outperforming the S&P 500+17% 6m✓
- IInstitutional sponsorshipmodel score 9/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
6/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Price is near or above the 30-week proxy, but the long average has stopped rising.